INNATE PHARMA (IPH.PA)
Develops experimental cancer immunotherapies that activate the immune system to fight tumors.
1.60-0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-13.8%
The outlook
IPH.PA is trading slightly above both its 50- and 200-day moving averages, placing it in the middle of its 52-week range. Analyst coverage appears limited based on available data. The overall sentiment leans bullish, though the stock remains modestly positioned within its recent trading band.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range49% of the way from its 52-week low to high
Market cap
—
52-wk high
2.20
52-wk low
1.03
50-day avg
1.60
200-day avg
1.50
Trailing P/E
—